GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.
Fiche publication
Date publication
janvier 2016
Journal
Journal of hematology & oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GUIDEZ Fabien
Tous les auteurs :
Guerenne L, Beurlet S, Said M, Gorombei P, Le Pogam C, Guidez F, de la Grange P, Omidvar N, Vanneaux V, Mills K, Mufti GJ, Sarda-Mantel L, Noguera ME, Pla M, Fenaux P, Padua RA, Chomienne C, Krief P
Lien Pubmed
Résumé
In spite of the recent discovery of genetic mutations in most myelodysplasic (MDS) patients, the pathophysiology of these disorders still remains poorly understood, and only few in vivo models are available to help unravel the disease.
Mots clés
Acute Disease, Animals, Disease Models, Animal, Gene Expression Profiling, methods, Gene Expression Regulation, Neoplastic, Humans, Leukemia, Myeloid, genetics, Mice, Mice, Transgenic, Myelodysplastic Syndromes, genetics, Oligonucleotide Array Sequence Analysis, methods, Reproducibility of Results, Reverse Transcriptase Polymerase Chain Reaction, Risk Factors, Signal Transduction, genetics
Référence
J Hematol Oncol. 2016 01 27;9:5